Search results
Results from the WOW.Com Content Network
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB. The medical standard for active TB is a short course treatment involving a combination of isoniazid , rifampicin (also known as Rifampin), pyrazinamide , and ethambutol for the first two months.
Directly observed treatment, short-course (DOTS, also known as TB-DOTS) is the name given to the tuberculosis (TB) control strategy recommended by the World Health Organization. [1] According to WHO, "The most cost-effective way to stop the spread of TB in communities with a high incidence is by curing it.
India had the highest total number of TB cases worldwide in 2010, in part due to poor disease management within the private and public health care sector. [226] Programs such as the Revised National Tuberculosis Control Program are working to reduce TB levels among people receiving public health care.
Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection caused by bacteria that are resistant to treatment with at least two of the most powerful first-line anti-TB medications (drugs): isoniazid and rifampicin. Some forms of TB are also resistant to second-line medications, and are called extensively drug-resistant TB .
Development of resistance is associated with poor management of cases. As of 2011, drug susceptibility testing is done in less than 5% of TB cases globally [3] Without testing to determine drug resistance profiles, MDR- or XDR-TB patients may develop resistance to additional drugs and can continue to spread the disease to others. TDR-TB is ...
The clinical presentation of abdominal tuberculosis is often atypical, tissue samples for confirmation of diagnosis can be difficult to procure and conventional diagnostic methods have poor yield. [1] Therefore, the diagnosis is often delayed. [1]
Extensively drug-resistant tuberculosis (XDR-TB) is a form of tuberculosis caused by bacteria that are resistant to some of the most effective anti-TB drugs. XDR-TB strains have arisen after the mismanagement of individuals with multidrug-resistant TB (MDR-TB). Almost one in four people in the world is infected with TB bacteria. [1]
In a recently published metaanalysis, [26] with data from both developed and developing countries, QuantiFERON-TB Gold In Tube had a pooled sensitivity for active TB of 81% and specificity of 99.2%, whereas T-SPOT.TB had a pooled sensitivity of 87.5% and specificity of 86.3%. In head-to-head comparisons, the sensitivity of IGRAs surpassed TST.